tbuckley/cabot-search huggingface dataset:
SAT0014 Association of Hla Genes in Systemic Sclerosis with Interstitial Lung Disease: Table 1.
Authors: H.M. Kwon, E.Y. Song, Y.J. Lee, J.K. Park, E.Y. Lee, Y.W. Song, E.B. Lee
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Interstitial lung disease (ILD) is associated with a significant morbidity and mortality in systemic sclerosis (SSc). Many studies have reported the association between human leukocyte antigen (HLA) alleles and increased risk of SSc, but the associated between ILD in SSc and HLA alleles remains unclear. <h3>Objectives</h3> The aim of this study was to investigate the association of HLA class I and HLA class II with ILD in Korean SSc cohort. <h3>Methods</h3> A total of 170 SSc patient (105 SSc patients with ILD and 65 SSc patients without ILD) were enrolled at Seoul National University Hospital from 1988 to 2014. Two hundred one healthy participants from Korean Marrow Donor Program (KMDP) were recruited as controls. Demographic information, clinical skin subset (limited vs. diffuse), SSc-specific autoantibodies (anti-topoisomerase I (ATA), anti-centromere (ACA), anti-ribonucleoprotein (RNP)), and internal organ involvement (ILD, pulmonary arterial hypertension, gastrointestinal, renal involvement) of the enrolled patients were characterized. ILD were diagnosed based on the findings of the chest computed tomography. HLA-A, -B, -C,-DQB1,-DRB1, and -DPB1 typing were performed PCR amplification with directly sequencing from extracted genomic DNA. <h3>Results</h3> HLA-B*52:01, C*12:02, DRB1*15:02, DPB1*09:01, and DPB1*13:01 alleles were more frequent in SSc patients with ILD than healthy controls. However, the frequencies of these genes did not differ between SSc patients with and without ILD (Table). ATA positive SSc was associated with HLA-B*52:01, C*12:02, DRB1*15:02, DPB1*09:01, and DPB1*13:01 alleles compared to ATA negative SSc and DPB1*09:01 showed the highest odds ratio for ATA (OR =23.08). <h3>Conclusions</h3> SSc patients with ILD have several specific HLA genes compared with healthy controls and the frequencies of these HLA genes were significantly higher in ATA-positive SSc as well. Therefore, ATA positivity and ILD are associated with ceratin HLA class I and II in SSc patients. <h3>References</h3> Zhou X, Lee JE, Arnett FC, Xiong M, Park MY, Yoo YK, et al. HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans. Arthritis Rheum 2009;60:3807–14. <h3>Disclosure of Interest</h3> None declared
Anti-Tumor Activity of a Novel Bcr-Abl/Lyn Dual Inhibitor, NS-187, in Murine CNS Ph+ Leukemia Models.
Authors: Asumi Yokota, Shinya Kimura, Tatsuya Oyama, Eishi Ashihara, Haruna Naito, Yoshimasa Urasaki, Takanori Ueda, Yasuhito Terui, Kiyohiko Hatake, Kazuko Hirabayashi, Taira Maekawa
Journal: Blood (2005)
Sirolimus for Graft-Versus-Host-Diseases Prophylaxis in Non-Myeloablative Matched Related Transplantation: Safety and Efficacy.
Authors: Hong Zheng, Michelle Carraher, Eric Schaefer, Giampaolo Talamo, W. Christopher Ehmann, Witold Rybka, David F. Claxton
Journal: Blood (2009)
Multiple Myeloma Patients ≤40 Years Of Age: Clinical Characteristics and Outcome In The Era Of Novel Agents
Authors: Argiris S. Symeonidis, Efstathios Kastritis, Sosana Delimpasi, Charikleia Kelaidi, Anastasia Sioni, Michalis Michael, Amalia Vassou, Anna Christoforidou, Panagiotis Repousis, Eudokia M. Mandala, Evangelos Terpos, Meletios A. Dimopoulos
Journal: Blood (2013)
Incident Type 2 Myocardial Infarction in a Cohort of Patients Undergoing Coronary or Peripheral Arterial Angiography
Authors: Hanna K. Gaggin, Yuyin Liu, Asya Lyass, Roland R. J. van Kimmenade, Shweta R. Motiwala, Noreen P. Kelly, Aditi Mallick, Parul U. Gandhi, Nasrien E. Ibrahim, Mandy L. Simon, Anju Bhardwaj, Arianna M. Belcher, Jamie E. Harisiades, Joseph M. Massaro, Ralph B. D’Agostino, James L. Januzzi
Journal: Circulation (2016)

Background: Despite growing recognition of type 2 myocardial infarction (T2MI; related to supply/demand mismatch), little is known about its risk factors or its association with outcome. Methods: A single-center cohort of patients undergoing coronary or peripheral angiography with or without intervention was prospectively enrolled and followed for incident type 1 and T2MI, and major adverse cardiovascular events (MACE, a composite of all-cause death, nonfatal myocardial infarction [MI], heart failure, stroke, transient ischemic attack, peripheral arterial complication, and cardiac arrhythmia), as well. T2MI was adjudicated using criteria from the Third Universal Definition of MI. Baseline characteristics, blood samples, and angiography information were obtained. Major end points subsequent to first MI were assessed using landmark analyses to compare the rates of first events only where everyone with a prior history of any MACE before MI were censored and adjusted for follow-up times. Cox proportional hazard models were used for time-to-event analyses with age and sex forced into all models and additional covariates evaluated by using the stepwise option for the selection. Results: One thousand two hundred fifty-one patients were enrolled and followed for a median of 3.4 years. Of these patients, 152 (12.2%) had T2MI during follow-up; T2MI was frequently recurrent. Multivariable predictors of T2MI were older age, lower systolic blood pressure, history of coronary artery disease, heart failure, chronic obstructive pulmonary disease, diabetes mellitus, nitrate use, and elevated concentrations of glucose, N-terminal pro-B type natriuretic peptide, and cystatin C. Patients with T2MI had higher rates of subsequent adverse events than those without T2MI (per 100 person-years: MACE, 53.7 versus 21.1, P &lt;0.001; all-cause death, 23.3 versus 3.3, P &lt;0.001; cardiovascular death, 17.5 versus 2.6, P &lt;0.001; heart failure events, 22.4 versus 7.4, P &lt;0.001); these rates are similar to those seen in patients with type 1 MI. Incident diagnosis of T2MI strongly predicted risk for subsequent MACE (adjusted hazard ratio, 1.90; 95% confidence interval, 1.46–2.48; P &lt;0.001), all-cause death (adjusted hazard ratio, 2.96; 95% confidence interval, 2.01–4.36; P &lt;0.001), and cardiovascular death (adjusted hazard ratio, 2.16; 95% confidence interval, 1.36–3.43; P =0.001). Conclusions: T2MI is common and associated with poor prognosis. Studies evaluating treatment strategies for management of T2MI are needed. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00842868.
PTU-028 Balloon Sphincteroplasty after Sphincterotomy: A Safe Way to Ensure a British Society of Gastroenterology ERCP Target is Achieved
Authors: P Wolfson, S Bouri, R Sayers, M Shariff, B Macfarlane, A King, A Leahy
Journal: Gut (2016)

<h3>Introduction</h3> Sphincterotomy and balloon/basket trawl at ERCP is the standard treatment to clear stones from the common bile duct. The BSG in 2014 published a key performance indicator of &gt;75% stone clearance during first ERCP. Balloon sphincteroplasty as an adjunct to sphincterotomy can increase stone clearance. The aim of this study is to review the success/safety for balloon sphincteroplasty compared to sphincterotomy alone. <h3>Methods</h3> Retrospective study between 1<sup>st</sup> April 2010–2014 in a large district general hospital of all ERCPs documenting a common bile duct stone. Electronic records were analysed with the following exclusion criteria: anticoagulants, biliary leak, unchecked cardiac device or incomplete follow up. Balloon sphincteroplasty was always performed after a sphincterotomy, using a Boston Scientific CRE wire guided balloon with a maximal diameter dilation that corresponded to the patient’s mid common bile duct diameter (8–15 mm). <h3>Results</h3> Total study population was 390 patients. Stone clearance with initial sphincterotomy alone and balloon/basket trawl was successful in 70% (n = 274) patients. 116 patients underwent additional balloon sphincteroplasty with a success rate of 85.5% (n = 100). The remaining patients underwent mechanical lithotripsy (n = 15) or tertiary care referral (n = 1). Therefore, sphincterotomy +/- balloon sphincteroplasty achieved stone clearance in 96% (n = 374) of patients. No statistically significant diferences were observed for complication rates when comparing sphincterotomy alone to balloon sphincteroplasty. Actual complication rates for sphincterotomy alone/balloon sphincteroplasty were: overall 5%/5.2%; pancreatitis 1%/2.6%; cholangitis 3%/3%; bleeding 3%/0% perforation 0%/0%. <h3>Conclusion</h3> Balloon sphincteroplasty is an effective and safe adjunct in patients who do not achieve bile duct stone clearance with sphincterotomy and balloon/basket trawl alone, allowing clearance rates to exceed current guideline recommendations. <h3>Reference</h3> 1 Wilkinson, <i>et al</i>. BSG ERCP – the way forward, A standards framework. 2014. http://www.bsg.org.uk <h3>Disclosure of Interest</h3> None Declared
Seizures During Infusion of Autologous Peripheral Blood Stem Cells Are Related to High White Blood Cell Concentration in the Peripheral Blood Stem Cell Product and Can Be Prevented by Dilution of Product with Autologous Plasma
Authors: Carlos Bachier, Grant Potter, Joshua Potter, Charles F. LeMaistre, Paul Shaughnessy, Kawah Chan, Veronica H. Jude, Renee Madden
Journal: Blood (2011)
Cytogenetic and Molecular Features of 1331 Chinese Patients with Primary Acute Lymphoblastic Leukemia (ALL).
Authors: Bing Chen, Xiang Wang, Ying Yao, Yong-Mei Zhu, Hai-Yan He, Xiao-Xing Jiang, Ji-Fang Zhou, Hai-Min Chen, Qi Cao, Guang Yang, Chun-Lei Jiang, Xiang-Qin Weng, Xu-Xi Zhang, Bo Jiao, Wei Li Zhao, Jun-Min Li, Yu Chen, Shu-Min Xiong, Zhi-Xiang Shen, Long-Jun Gu, Hui Jiang, Jian-Qing Mi, Zhu Chen, Sai-Juan Chen
Journal: Blood (2009)
AB0382 Prevention of Venous Thromboembolism (Vte) after Total Knee Replacement in Patients with Rheumatoid Arthritis
Authors: A. Rybnikov, E. Byalik, T. Reshetnyak, S. Makarov, M. Makarov, V. Pavlov, A. Khramov, E. Naryshkin
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In this study, we analyzed incidences of VTE in patients with rheumatoid arthritis (RA) and osteoarthritis (OA) after total knee or hip arthroplasty, compared schemes of drug prevention and evaluated their efficiency. <h3>Objectives</h3> To evaluate the efficiency of prevention of VTE in patients with rheumatoid arthritis and osteoarthritis after total knee replacement under comparable conditions <h3>Methods</h3> We studied 151 patients operated in V.A. Nasonova Research Institute of Rheumatology for the period 2014–2015. Of these, 72 patients with RA (47.7%) and 79 patients with OA (52.3%). For a comparative analysis of the efficiency of anticoagulant therapy, each patient group was divided into 2 subgroups by type of drug therapy. The first - nadroparin calcium (the drug therapy was started for 12 hours after the operation at a dose of 0.1 ml per 10 kg of body weight one time per day), the second - nadroparin calcium with transfer to dabigatran etexilate (the first stage of 4 hours after the operation was started therapy by nadroparin calcium, and then after the removal of the epidural catheter moved to the dabigatran etexilate).Doppler ultrasonography (DUS) was routinely performed preoperatively and on postoperative day 7, 14, then 1 time a month for diagnosing a deep venous thrombosis (DVT). Time of observation was 6 months. <h3>Results</h3> VTE were reported in 6 (3.9%) patients, 1 of them (0.7%) with RA and 5 (3.3%) with OA. Distal deep vein thrombosis developed on 15 days after total knee replacement in RA patient. He received nadroparin calcium only. 4 patients with VTE after surgery from OA group used nadroparin calcium and 1 patient was on combined drug therapy. Of the 6 cases of VTE 4 (66.7%) were asymptomatic and 2 (33.3%) with development of clinical and laboratory picture. The case of thrombosis in a group of RA was asymptomatic. In a perioperative period of clinically significant bleeding was not seen. <h3>Conclusions</h3> Cases of VTE in patients with RA, despite the large number of risk factors, under comparable conditions is significantly lower than patients with OA. The number of asymptomatic deep vein thrombosis prevails over the development of clinical and laboratory complex of symptoms in both groups. In patients with RA and OA who were from the first group have reported 5 cases of VTE and only 1 case of VTE have reported in patients who were from second group. Combined drug VTE prevention in patients with RA and OA has been most effective and safe. <h3>Disclosure of Interest</h3> None declared
SAT0139 Maximum Methotrexate Dose Seem To Be An Only Risk Factor for Development of MTX-Associated Lymphoproliferative Disorders
Authors: T. Higuchi, Y. Higuchi, S. Fuke, T. Takagi, D. Suzuki, Y. Koyama
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Since February 2011, an approved Methotrexate (MTX) dose for rheumatoid arthritis: RA treatment has been raised from 8mg/wk to 16mg/wk in Japan. Recently, we have an impression that incidence of MTX-associated lymphoproliferative disorders (MTX-LPD) are increasing. <h3>Objectives</h3> To investigate incidence and etiology of MTX-LPD. <h3>Methods</h3> All of adult patients receiving MTX for treatment of autoimmune diseases (n=244) in our hospital from May 2012, to August 2015 are surveyed. In each case, the possible risk factors for development of MTX-LPD including minimum MTX dose, maximum MTX dose, administration period, and cumulative dose were investigated in detail. In order to detect the important risk factors, Cox proportional hazards regression analysis (Cox model) were carried out. <h3>Results</h3> At baseline, the background of the patients were as follows: male-to-female ratio was 4:3, age was 72.3±8.5 years, minimum MTX dose was 5.4±1.0mg/wk, maximum MTX dose was 10.9±3.6mg/wk, administration period was 274.4±379.7wk, and all cumulative dose was 1842.3±1358.1mg. By the end of 2015, seven of patients developed (six RA, one psoriatic arthritis: PsA). The incidence was accounted for 2.9% in all amenable patients by following up for 119 weeks on average. By Kaplan-Meier plots, incidence of MTX-LPD was 0.85% at up to 52weeks and 9.2% at up to 260weeks. Cox model analysis revealed that maximum MTX dose was the only independent risk factor for MTX-LPD development. The annual incidence of MTX-LPD increases 1.58 times with 1mg increment of MTX (p=0.009, 95%CI 1.12–2.25). The seven MTX-LPD cases include three DLBCL, two indeterminable, and one Hodgkin9s lymphoma. The last one had both Follicular and Hodgkin9s lesions. The EBV in blood level was significantly elevated in all checked cases, and EBER was positive in six specimens of five cases by histopathological inspection. All of the lymphoproliferative lesions regressed spontaneously after MTX was withdrawn. <h3>Conclusions</h3> In our cohort, the incidence of MTX-LPD was quite frequent as compared to previous Japanese report (0.5%; before 2011) or reports from worldwide (0.05–0.3%). It is of particular interest that the annual incidence of MTX-LPD increases 1.58 times with only 1mg increment of MTX a week. It is also notable that all of the lesions regressed spontaneously so far after cessation of MTX, and the connection with EBV infection was found in all investigated cases. Although our cohort is rather small, we believe that it is worth to survey why the incidence of MTX-LPD are increasing in Japan with a larger cohort study. It may reveal the etiology of MTX-LPD in detail. <h3>Disclosure of Interest</h3> None declared
SAT0140 Prevalence of Reactivation of Hepatitis B Virus (HBV) in Patients with Resolved Hbv Hepatitis on Immunosuppressive Therapy for Rheumatic Disease: Multicentre Prospective Observational Study in Japan
Authors: W. Fukuda, T. Hanyu, M. Katayama, A. Okada, S. MIzuki, M. Miyata, Y. Handa, M. Hayashi, Y. Koyama, K. Arii, T. Kitaori, H. Hagiyama, Y. Urushidani, T. Yamazaki, Y. Ikeno, T. Suzuki, S. Inokuma
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Although the reactivation of hepatitis B virus (HBV) is recognized as a serious complication in patients with connective tissue disease (CTD) receiving immunosuppressive drugs (ISDs), the incidence and risk factors of reactivation remain controversial. <h3>Objectives</h3> We performed a multicentre, observational, prospective study across 16 Japanese Red Cross hospitals to clarify the prevalence and pathophysiology of HBV reactivation in patients with CTD. We report the results of 2-year observations in patients with resolved HBV infection. <h3>Methods</h3> Patients with CTD, treated with a dose of ≥5 mg/day prednisolone, and/or synthetic or biological ISDs, with negative HBs antigen and positive anti HBs and/or HBc antibody (Ab), were enrolled. HBV-DNA (RT-PCR) and related data were registered regularly. <h3>Results</h3> Among 1040 patients, including 950 rheumatoid arthritis, HBV-DNA was detected in 32 patients (1.75/100 person-years), and &gt;2.1 log copy/ml was observed in 9 cases (0.49/100 person-years) over 1–2 years of observation. None of the reactivated patients, including six treated with a nucleic acid analogue, showed overt hepatitis. Low HBs Ab titres and advanced age seemed to be risk factors for HBV reactivation; however, reactivation was observed in 3 patients with positive HBs Ab and negative HBc Ab. The risk of reactivation among the different types of ISDs was not statistically different. The intervals from the start of ISD to reactivation were longer than previous reports (4–157 months, average 58.9 months). <h3>Conclusions</h3> HBV reactivation with ISD was 1.75/100 person-years in CTD patients with resolved HBV infection. Overt hepatitis was observed in none of the reactivated patients, and low HBs antibody titres and advanced age were risk factors for reactivation. Patients with positive HBs Ab and negative HBc Ab are not free from the risk of reactivation of HBV. <h3>References</h3> B. J Hepatol 2012: 57. 167–185 <h3>Disclosure of Interest</h3> None declared
Assessment of Individual Characteristics on the Pharmacokinetics of Oral Busulfan in Adults Patients Undergoing Hematopoietic Stem-Cell Transplantation.
Authors: Philippe Bouchard, Sarah Bilodeau, Karine Alain, Barbara Vadnais, Martin Franco, Lambert Busque, Denis-Claude Roy, Benoît Pronovost, Véronique Michaud, Jacques Turgeon BPharm
Journal: Blood (2007)
SAT0096 Indicators and Frequency of Hip Synovitis Detected by Ultrasound in RA:
Authors: A.A. Negm, A.-S. Mohamed, A. Abonar, E. Abdulazim, S. AL Araby
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Large joints affection including the hip in RA has significant impact on patient9s activity. Unfortunately, clinical detection of hip synovial hypertrophy and effusion is difficult, while Ultrasound is reliable and effective to compensate for such problem<sup>1</sup>. <h3>Objectives</h3> Identify clinical and Laboratory characteristics associated with Ultrasonographic hip synovitis among RA Patients <h3>Methods</h3> We conducted an observational cohort study on 60 RA adult patients fulfilling the 1987 ACR classification Criteria for RA. Exclusion criteria include those with non- RA related Hip Arthritis (Degenerative, Traumatic, Metabolic and referred pain from the back). Grouping: Group I, 30 patients complaining of hip pain and Group II 30 without hip pain. All patients had full history and clinical examination including DAS28, SJC66, TJC68, Patient and Physician Global Assessment of disease activity (PTGA, PGA); and Lab includes ESR, CRP and RF. Ultrasound examination was done according to the standard EULAR guidelines. <h3>Results</h3> The following table shows the demographic, clinical and lab characheteristics of both groups. The initial intra-group analysis showed no statistically significant difference in all the measurable demographic, clinical and laboratory data between patients with Normal and Abnormal US. Except for duration of symptoms of hip pain in Group I (16.3±9.6 weeks in those with abnormal US vs 4.4±2.3 weeks in those with normal US Scan (P&lt;0.001) by using point Biserial correlation. Regarding US, Synovial Hypertrophy/ effusion (Abnormal US) was found in 14 out of 30 patients (46.7%) in Group I and 10 out of 30 (33.33%) in group II with no significant difference (P=0.29). Further whole group analysis showed that CRP was statistically significantly higher in patients with abnormal Hip US (24/60 patients) 8.25±5.25 mg/dl than those with normal Hip US (36/60 patients) 5.17±5.58 mg/dl (P=0.036). In addition, Knee effusion and synovial thickening detected by clinical examination was more frequent in patients with abnormal Hip US (than those with normal hip US, 41.7% vs 13.8% (P=0.015). <h3>Conclusions</h3> Hip joint is frequently affected in RA and searching for hip joint involvement should not be limited to those complaining of hip pain to exclude subclinical hip involvement. Apart from CRP, duration of hip symptoms and knee affection, there was no significant correlation between abnormal US and demographics or laboratory data. <h3>References</h3> Di Geso L1, Filippucci E, Riente L, et al. (2012) Ultrasound imaging for the rheumatologist XL. Sonographic assessment of the hip in rheumatoid arthritispatients. Clin Exp Rheumatol. 30(4):464–8. <h3>Disclosure of Interest</h3> None declared
Clinico-Pathological Characteristics of B-Cell Non Hodgkins Lymphomas Associated with Hepatitis C Virus ANRS HC13 LYMPHO-C Observational Study.
Authors: Caroline Besson, Danielle Canioni, Catherine Settegrana, Henda Driss, Laurent Alric, Patrice Cacoub, Cyrille Feray, Felipe Suarez, Florence Nguyen Khac, Helene Merle-Beral, Frederic Davi, Olivier Hermine
Journal: Blood (2009)